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Summary
Non-transfusion-dependent thalassaemias (NTDT) encompass a spectrum
of anaemias rarely requiring blood transfusions. Increased iron absorption,
driven by hepcidin suppression secondary to erythron expansion, initially
causes intrahepatic iron overload. We examined iron metabolism biomark-
ers in 166 NTDT patients with b thalassaemia intermedia (n = 95), haemo-
globin (Hb) E/b thalassaemia (n = 49) and Hb H syndromes (n = 22).
Liver iron concentration (LIC), serum ferritin (SF), transferrin saturation
(TfSat) and non-transferrin-bound iron (NTBI) were elevated and corre-
lated across diagnostic subgroups. NTBI correlated with soluble transferrin
receptor (sTfR), labile plasma iron (LPI) and nucleated red blood cells
(NRBCs), with elevations generally confined to previously transfused
patients. Splenectomised patients had higher NTBI, TfSat, NRBCs and SF
relative to LIC, than non-splenectomised patients. LPI elevations were con-
fined to patients with saturated transferrin. Erythron expansion biomarkers
(sTfR, growth differentiation factor-15, NRBCs) correlated with each other
and with iron overload biomarkers, particularly in Hb H patients. Plasma
hepcidin was similar across subgroups, increased with >20 prior transfu-
sions, and correlated inversely with TfSat, NTBI, LPI and NRBCs. Hep-
cidin/SF ratios were low, consistent with hepcidin suppression relative to
iron overload. Increased NTBI and, by implication, risk of extra-hepatic
iron distribution are more likely in previously transfused, splenectomised
and iron-overloaded NTDT patients with TfSat >70%.
Keywords: non-transfusion-dependent thalassaemia, iron overload,
ineffective erythropoiesis, anaemia.
Non-transfusion-dependent thalassaemias (NTDT) comprise
a heterogeneous group of anaemias characterised by
impaired production of b-globin and/or a-globin chains,
for which ineffective erythropoiesis is the underlying mech-
anism for anaemia (Vichinsky, 2007; Fucharoen & Vipraka-
sit, 2009; Galanello & Origa, 2010; Harteveld & Higgs,
2010). Three main diagnostic subgroups have been
identified: b thalassaemia intermedia (b TI), haemoglobin
(Hb) E/b thalassaemia and Hb H syndromes (Weatherall,
2012). Management strategies are highly diverse, and may
include close observation, sporadic transfusion, splenec-
tomy and Hb F-inducing agents (Taher et al, 2011;
Fucharoen & Weatherall, 2012; Musallam et al, 2012;
Vichinsky, 2013).
Patients with NTDT, as well as other iron-loading anae-
mias, become iron overloaded mainly because of increased
iron absorption (Pippard et al, 1979; Pootrakul et al, 1988),
which averages 0011 mg/kg/day in the absence of transfu-
sion therapy (Taher et al, 2012); sporadic transfusions also
directly contribute to further iron accumulation. However,
the parameters accounting for variability in iron absorption
across the range of NTDT diagnostic subgroups are not well
described (Table SI). In principle, iron accumulation could
be increased in line with the degree of anaemia and/or by
erythroid expansion, both driving down synthesis of the iron
regulatory protein hepcidin and hence increasing dietary iron
absorption. Bone-marrow-derived factors associated with
ineffective erythropoiesis have been implicated in inhibiting
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hepcidin synthesis, including growth differentiation factor 15
(GDF-15) in humans (Tanno et al, 2007; Tanno & Miller,
2010) and, more recently, erythroferrone in mice (Kautz
et al, 2014). In addition, GDF-11 has recently been identified
as a key factor associated with ineffective erythropoiesis in a
mouse model of thalassaemia (Dussiot et al, 2014). The same
mechanism will also increase the release of recycled iron
from the reticuloendothelial system, thus depleting macro-
phage iron. This typically explains the preferential periportal
and hepatocyte iron loading with increased liver iron concen-
tration (LIC) (Origa et al, 2007; Taher et al, 2009a, 2011;
Gardenghi et al, 2010; Tanno & Miller, 2010). Chronic anae-
mia and hypoxia also induce expression of hypoxia-inducible
transcription factors (Tanno & Miller, 2010) and stimulate
erythropoietin (EPO) synthesis, thus inducing erythropoiesis
and erythron expansion, which further augments iron
absorption.
The THALASSA (Assessment of Exjade in Non-Transfu-
sion-Dependent Thalassaemia) trial was a prospective, ran-
domised, double-blind, placebo-controlled, Phase II clinical
trial of deferasirox, which enrolled 166 patients with the
three primary diagnostic groups of NTDT and considerable
iron burden (Taher et al, 2012). The current analyses of
baseline data from the large THALASSA database (prior to
treatment with deferasirox) examined how erythropoietic
and iron metabolism markers inter-relate within NTDT diag-
nostic subgroups. With the associations between ineffective
erythropoiesis, chronic anaemia and gastrointestinal iron
absorption that lead to iron loading in patients with NTDT,
we hypothesised that LIC would be associated with biomark-
ers of iron turnover, anaemia and erythroid expansion, par-
ticularly in untransfused and unchelated patient subgroups.
Baseline markers of iron storage (serum ferritin and LIC)
and iron turnover (transferrin saturation [TfSat], non-trans-
ferrin-bound iron [NTBI] and labile plasma iron [LPI]) were
examined, as well as markers of erythroid expansion (soluble
transferrin receptor [sTfR], GDF-15 and nucleated red blood
cells [NRBCs]). Markers of anaemia (Hb and EPO) were
compared between the NTDT subgroups and related to the
iron metabolism markers. Plasma hepcidin was measured in
all subgroups at baseline and related to markers of iron stor-
age, iron turnover, erythroid expansion, anaemia and hypox-
ia. The effects of previous management strategies
(splenectomy and prior transfusion therapy) on these
markers were also examined.
Methods
Study design
THALASSA was a multinational, prospective, randomised,
double-blind, placebo-controlled, Phase II study (ClinicalTri-
als.gov number NCT00873041) for which the study design
and inclusion/exclusion criteria have been described previ-
ously (Taher et al, 2012). Briefly, male or female patients
aged ≥10 years with NTDT, iron overload (LIC ≥5 mg Fe/g
dry weight [dw] by R2 magnetic resonance imaging [MRI])
and serum ferritin >300 lg/l who received no transfusions
within 6 months or chelation therapy within 1 month before
study entry were included. Patients with previous exposure
to deferasirox were excluded, although patients may have
received deferoxamine (DFO), deferiprone or a combination
of the two. Additional exclusion criteria included Hb S vari-
ants of thalassaemia syndromes, active hepatitis B or hepatitis
C, cirrhosis, alanine aminotransferase levels >5 9 the upper
limit of normal (ULN), serum creatinine >ULN or creatinine
clearance ≤60 ml/min on two consecutive measurements, or
significant proteinuria (urine protein/urine creatinine ratio
>10 mg/mg) on two consecutive measurements. Patients (or
parents/guardians) provided written, informed consent prior
to enrolment. No patients received any transfusions within
6 months or chelation therapy within 1 month prior to
enrolment. The study was conducted in accordance with
Good Clinical Practice guidelines and the Declaration of
Helsinki and was approved by the local ethics committees of
the study sites.
Assessments
The THALASSA trial included an initial screening period of
4 weeks, composed of two visits at least 14 days apart. Dur-
ing screening, LIC was measured at one visit using a vali-
dated R2 MRI technique (FerriScan, Resonance Health,
Claremont, Australia) and adopted as the baseline measure-
ment (St Pierre et al, 2005). Serum ferritin levels were mea-
sured at both screening visits, and baseline levels were
calculated from the mean of the two measurements (with a
minimum time lag of 14 days between the two assess-
ments). NRBCs and plasma Hb levels were also measured
at both screening visits. TfSat, sTfR, NTBI, LPI, EPO, hep-
cidin and GDF-15 were measured at baseline (pre-dose).
TfSat was directly measured using the urea gel method and
NTBI was detected using high-performance liquid chro-
matography at University College London, London, UK, as
described elsewhere (Lal et al, 2013; Porter et al, 2014). The
LPI assay (FeROSTM LPI, Aferrix Ltd., Tel Aviv, Israel) was
performed using methods described previously (Esposito
et al, 2003). Plasma hepcidin was determined at King’s Col-
lege London, London, UK (Bansal et al, 2009). All remain-
ing blood chemistry samples were analysed at a central
laboratory.
Statistical methods
Demographic and other baseline data (including disease
characteristics) are summarised descriptively. All analyses
were performed for all patients and by diagnostic subgroup:
b TI, Hb E/b thalassaemia and Hb H syndromes. Correla-
tions were assessed by Pearson’s correlation coefficients and
scatter plots, with simple linear regression models; GDF-15
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and EPO were analysed as log values for these analyses.
Nominal P-values are provided and were considered
significant when <005.
Results
Baseline demographics and patient characteristics
In total, 166 patients were enrolled (Table I). Most patients
had b TI (n = 95, 572%) or Hb E/b thalassaemia (n = 49,
295%), while the remaining 133% (n = 22) had predomi-
nantly Hb H syndromes (Hb H disease [n = 8], Hb H-CS
[n = 6], genotype not determined [n = 6], HbH-CS and
heterozygous HbE [CSEA] Bart’s [n = 1] or Hb Agrino
[n = 1]). Age was similar across all groups. Splenectomy,
previous transfusions and prior chelation therapy were least
frequent in patients with Hb H syndromes and most likely in
b TI patients (Table I). Splenectomy was less frequent in
patients with Hb E/b thalassaemia than in patients with b
TI. Previous chelation therapy was most frequent in patients
with b TI (40%) and least frequent in patients with Hb H
syndromes (5%). The proportion of patients who received
sporadic or more frequent transfusions and the median
number of transfusions were similar across diagnostic
subgroups.
Anaemia and erythropoietic biomarkers
Baseline levels. All patient subgroups were anaemic with ele-
vated EPO levels (Table II). However, Hb levels were notably
higher and EPO levels lower in patients with Hb H syn-
dromes compared with other diagnostic subgroups, while Hb
levels were lowest in patients with Hb E/b thalassaemia.
Markers associated with ineffective erythropoiesis (sTfR,
GDF-15 and NRBC) were also lowest in patients with Hb H
syndromes (Table II).
Relationships between anaemia, erythropoiesis and iron meta-
bolism. There was a negative correlation between Hb and
EPO in the overall population as expected (r = 035;
P < 00001; Table SII). The EPO-to-Hb relationship was
stronger in patients with Hb H syndromes (r = 076;
P < 00001) than in patients with Hb E/b thalassaemia
(r = 042; P = 00028) and b TI (r = 032; P = 00022).
Across all patients, sTfR was negatively related to Hb levels
(r = 046; P < 00001; Fig 1A) and positively correlated
with EPO (r = 047; P < 00001; Fig 1B). This was also evi-
dent by diagnostic subgroup (Tables SIII, SIV and SV). A
negative relationship was present between Hb and NRBCs
(r = 046, P = 00016) and between Hb and sTfR
(r = 042, P = 00024) in patients with Hb E/b thalas-
saemia (Table SIV), consistent with more severe anaemias
driving increased erythropoiesis; no relationship between Hb
and GDF-15 was apparent.
Iron overload and iron metabolism biomarkers
Baseline levels. Across all diagnostic subgroups, markers of
iron storage (LIC and serum ferritin) were raised but similar.
Iron turnover biomarkers (TfSat and NTBI) were elevated
above normal ranges with lower TfSat and NTBI in patients
with Hb H syndromes (Table II). Overall, median TfSat was
88% (range 240% to 1000%); 34/158 (215%) patients with
TfSat measured at baseline had 100% TfSat, which contrasts
with transfusion-dependent (TDT) patients, in whom TfSat
is typically 100%. LPI was generally not detectable across all
subgroups, but reached levels above normal (>04 units) in
22 patients overall (b TI, n = 16; Hb E/b thalassaemia,
Table I. Baseline demographics and patient characteristics by underlying disease.
Characteristic
All patients
(n = 166)
b TI
(n = 95)
Hb E/b thalassaemia
(n = 49)
Hb H syndromes
(n = 22)
Age at screening, years
Mean  SD 321  120 330  117 277  111 377  124
Median (range) 315 (10–69) 330 (11–69) 270 (10–52) 355 (18–60)
Splenectomy, n (%) 88 (530) 67 (705) 18 (367) 3 (136)
Transfused previously (sporadic), n (%) 145 (873) 80 (842) 47 (959) 18 (818)
Median (range) number of
previous transfusions*
8 (1–75) 10 (1–75) 6 (1–47) 6 (1–43)
Patients with 1–<10, n (%) 76 (458) 38 (400) 29 (592) 9 (409)
Patients with ≥10,†n (%) 65 (392) 39 (411) 18 (367) 8 (364)
Previous chelation therapy,‡n (%) 44 (265) 37 (389) 6 (122) 1 (45)
b TI, b thalassaemia intermedia; Hb, haemoglobin; SD, standard deviation.
The proportion of patients who received sporadic or more frequent transfusions was similar across diagnostic subgroups.
*Patients did not receive any transfusion in the 6 months prior to study entry and data were missing in four patients.
†Data were missing in four patients.
‡Patients did not receive any chelation therapy within 1 month prior to study entry and patients with previous exposure to deferasirox were
excluded.
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n = 5; Hb H syndromes, n = 1). Hepcidin levels were gener-
ally within the normal range, although slightly lower in b TI
patients than in the other two patient subgroups (Table II).
The hepcidin/serum ferritin ratio was similar for all diagnos-
tic subgroups (Table II) and notably less than that described
elsewhere in TDT and sickle-cell disease (SCD) patients,
using similar methodology for plasma hepcidin measurement
(Porter et al, 2014). This is consistent with hepcidin suppres-
sion relative to iron overload in NTDT patients across all
subgroups. Hepcidin levels were highest in patients with a
history of >20 blood transfusions, despite serum ferritin and
LIC being no higher in this group.
Relationships between iron storage, iron turnover and hep-
cidin. Strong correlations were seen between LIC and serum
ferritin overall (r = 064; P < 00001) and in all diagnostic
subgroups (Tables SIII, SIV and SV), with similar slopes
(data not shown). TfSat correlated with NTBI (r = 084;
P < 00001), LIC (r = 037; P < 00001), serum ferritin
(r = 035; P < 00001) and LPI (r = 030; P = 00002; Fig 2).
The relationship between TfSat and NTBI was continuous
(Fig 2C), whereas the relationship between TfSat and LPI
appeared binary or possibly hyperbolic, with LPI absent (ex-
cept in four cases) when TfSat was <98% (Fig 2D). This may
explain the apparent absence of LPI across diagnostic sub-
groups, as TfSat was typically <100% (Table II). NTBI also
correlated with LIC (r = 035; P < 00001; Fig 3A) and
serum ferritin (r = 039; P < 00001; Fig 3B). The relation-
ships between iron storage and iron turnover parameters
were generally stronger in patients with Hb E/b thalassaemia
and Hb H syndromes than in b TI patients (Tables SIII, SIV
and SV). Moderate-to-strong correlations between hepcidin
and both TfSat and NTBI were identified (r = 033;
P < 00001 and r = 024; P = 00029, respectively; Fig 4A
and 4B). There was no correlation between hepcidin and
markers of iron storage (Table SII). This was consistent
across underlying diseases (Tables SIII, SIV and SV).
Relationships between erythroid expansion, iron metabolism
and hepcidin. Evaluable biomarkers of erythroid expansion
generally correlated with each other. Overall, there were
strong, positive associations between sTfR and GDF-15
(Fig 1C) and between sTfR and NRBCs (Fig 1D). Moderate,
yet significant, correlations between markers of erythron
expansion (sTfR, NRBC and GDF-15) and iron turnover
were also identified (Table SII): NTBI and sTfR (r = 020;
P = 0013); NTBI and NRBC (r = 023; P = 00041); TfSat
and GDF-15 (r = 017; P = 00402); and TfSat and NRBC
(r = 026; P = 00014). These correlations were generally
stronger in patients with Hb E/b thalassaemia or Hb H syn-
dromes (Tables SIV and SV). Markers of erythron expansion
(sTfR, NRBC and GDF-15) were not correlated with those of
iron storage in patients as a whole, although relationships
were identified in patients with Hb H syndromes: between
LIC and sTfR (r = 044; P = 004) and between LIC and
GDF-15 (r = 047; P = 0027). This may be because most of
these patients had not received prior chelation therapy,
unlike the other diagnostic subgroups. Hepcidin generally
did not correlate with markers of erythroid expansion
(GDF-15 or sTfR; Table SII) except in patients with Hb E/b
thalassaemia, where a significant inverse correlation between
hepcidin and GDF-15 was seen (r = 03; P = 00084).
Table II. Baseline anaemia, erythroid expansion, iron storage and iron turnover biomarkers in all patients and by diagnostic subgroup.
Parameter,
median (range)
All patients
(n = 166)
b TI
(n = 95)
Hb E/b
thalassaemia (n = 49)
Hb H
syndromes (n = 22)
Laboratory
normal ranges
Hb, g/l 810 (470–1400) 840 (470–1400) 720 (500–930) 910 (550–1060) 113–175
EPO, u/l 1010 (183–34050) 1080 (183–34050) 1150 (191–6490) 570 (261–4030) 37–315
NRBC,/100 WBC 453 (00–8275) 1285 (00–8275) 180 (00–6310) 100 (00–170) 0
sTfR, mg/l 287 (83–643) 279 (83–565) 305 (174–513) 249 (116–643) 19–50
GDF-15, ng/l 9144 (689–53 730) 10,864 (1075–53 730) 9114 (1748–31 667) 2081 (689–6515) 337–1060
Serum ferritin, lg/l 992 (304–6419) 956 (304–3176) 1050 (393–6419) 1084 (330–3365) 15–400
LIC, mg Fe/g dw 121 (26–491) 117 (26–491) 147 (50–421) 113 (62–346) <181
TfSat, % 880 (240–1000) 885 (240–1000) 880 (320–970) 770 (421–983) 20–55
NTBI, lmol/l* 22 (–32–85) 18 (–32–85) 26 (–17–55) 18 (–27–75) 03–15
LPI, LPI units 00 (00–29) 00 (00–29) 00 (00–17) 00 (00–24) 0–04
Hepcidin, nmol/l 44 (01–510) 38 (01–510) 56 (08–387) 50 (12–157) 20–75
Hepcidin/serum
ferritin ratio1000
50 (00–500) 40 (00–400) 60 (00–500) 50 (00–500) 2322
b TI, b thalassaemia intermedia; dw, dry weight; EPO, erythropoietin; GDF-15, growth differentiation factor 15; Hb, haemoglobin; LIC, liver iron
concentration; LPI, labile plasma iron; NRBC, nucleated red blood cell; NTBI, non-transferrin-bound iron; sTfR, soluble transferrin receptor;
TfSat, transferrin saturation; WBC, white blood cells.
All patient subgroups were anaemic, with elevated iron metabolism parameters above the normal ranges, although LPI was generally not detected
Note: Baseline is defined as the average of all values measured before or on the day of the first dose of study medication.
*Negative values can be interpreted as NTBI being absent from the sample; 1(St Pierre et al, 2005); 2(Porter et al, 2014).
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A significant inverse relationship between hepcidin and
NRBCs was also identified overall (r = 021; P = 00081),
as well as in patients with Hb E/b thalassaemia (Table SII).
Effects of previous management: transfusion and
splenectomy
Prior blood transfusion. The majority of patients received
sporadic transfusions prior to enrolment (Table I), with a
median of eight lifetime transfusion episodes, although the
number was highly variable (range 1–75; Table I). A higher
proportion of patients with Hb H syndromes received no
prior transfusions (227% Hb H syndromes vs 187% b TI
and 41% Hb E/b thalassaemia patients). Nearly all Hb E/b
thalassaemia patients had previously received transfusion
therapy, possibly because patients were more anaemic (me-
dian Hb levels 720 g/l). Patients with prior transfusions gen-
erally had lower Hb levels and higher NRBCs and EPO,
indicative of a greater degree of ineffective erythropoiesis, as
well as increased iron storage and iron turnover biomarkers
(Table III). LIC and serum ferritin levels were not related to
the number of previous transfusions, presumably because of
previous chelation therapy. TfSat and sTfR levels progres-
sively increased in patients who received more transfusions.
Hepcidin levels were also notably increased in patients who
had received >20 previous transfusions. NTBI was generally
absent in patients in the absence of prior transfusions (the
majority were b TI patients; Table I), in contrast to
transfused patients.
Prior splenectomy. Overall, 53% (n = 88) of patients were
splenectomised (Table I). In splenectomised versus non-sple-
nectomised patients, median (range) serum ferritin levels and
LIC were slightly elevated [1116 lg/l (370–6419) vs 834 lg/l
(304–3365) and 129 mg Fe/g dw (26–393) vs 116 mg Fe/g
dw (50–491), respectively]. The relationship between LIC
Fig 1. Correlations between sTfR and (A) Hb (B) NTBI (C) GDF-15 and (D) NRBCs. Evaluable biomarkers of erythroid expansion generally cor-
related with each other. The strong negative correlation of Hb levels with sTfR supports the concept that sTfR levels reflect erythroid mass, which
increases with greater anaemia. GDF-15, growth differentiation factor-15; Hb, haemoglobin; NRBC, nucleated red blood cells; NTBI, non-trans-
ferin-bound iron; sTfR, soluble transferrin receptor.
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Fig 2. Correlations between TfSat and markers of iron storage: (A) LIC and (B) serum ferritin; and markers of iron turnover: (C) NTBI and (D)
LPI. The relationship between TfSat and NTBI was continuous, whereas the relationship between TfSat and LPI appeared binary. b TI, b thalas-
saemia intermedia; dw, dry weight; Hb, haemoglobin; LIC, liver iron concentration; LPI, labile plasma iron; NTBI, non-transferrin-bound iron;
TfSat, transferrin saturation.
Fig 3. Correlations between NTBI and markers of iron storage: (A) LIC and (B) serum ferritin. Strong correlations were noted between NTBI
as a marker of iron turnover and LIC and serum ferritin, markers of iron storage. dw, dry weight; LIC, liver iron concentration; NTBI, non-
transferrin-bound iron.
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and serum ferritin differed in splenectomised patients
(r = 0764; P < 00001 [n = 88]) versus non-splenectomised
patients (r = 0552; P < 00001 [n = 77]), as the serum fer-
ritin increment was greater in relation to LIC in splenec-
tomised patients (Fig 5). No differences were noted between
LIC and other markers of iron metabolism, TfSat and NTBI
(data not shown). However, both NTBI and TfSat were nota-
bly higher in splenectomised versus non-splenectomised
patients [25 lmol/l (19–85) vs 06 lmol/l (32–75)
and 910% (430–1000) vs 780% (240–983), respectively;
Fig 6A, B). Splenectomised patients also had higher median
(range) GDF-15 levels and NRBCs than non-splenectomised
patients (Fig 6C, D): 10 300 ng/l (1075–53 730) versus
7903 ng/l (689–46 511) and 2350/100 white blood cells
(WBC) (35–8275) vs 40/100 WBC (00–560), respectively.
Levels of EPO and Hb were similar: 1010 u/l (183–34050)
vs 1010 u/l (191–19570) and 810 g/l (470–1180) vs
810 g/l (550–1400), respectively.
Discussion
To our knowledge, this is the first study to compare a range
of biomarkers of iron metabolism and erythropoiesis, includ-
ing plasma hepcidin, across a range of diagnostic NTDT
Fig 4. Correlations between hepcidin and markers of iron turnover: (A) TfSat and (B) NTBI. Hepcidin correlated with markers of iron turnover,
but not markers of iron storage. b TI, b thalassaemia intermedia; dw, dry weight; NTBI, non-transferrin-bound iron; TfSat, transferrin saturation.
Table III. Iron and haematological parameters in all patients by number of previous transfusions.
Parameter, median (range)
Number of previous transfusions
0 (n = 21) 1–<10 (n = 76) 10–20 (n = 46) >20 (n = 19)
Serum ferritin, lg/l 622 (304–1473) 1054 (374–6419) 1085 (370–3065) 988 (342–3365)
LIC, mg Fe/g dw 74 (58–286) 135 (50–421) 130 (26–491) 107 (51–322)
TfSat, % 720 (260–920) 880 (320–1000) 895 (290–983) 805 (240–950)
NTBI, lmol/l* –003 (–28–40) 239 (–32–85) 24 (–20–75) 16 (–17–50)
LPI, LPI units 00 (00–04) 00 (00–19) 00 (00–29) 00 (00–08)
Hepcidin, nmol/l 42 (01‒103) 43 (03‒510) 42 (01‒209) 69 (05‒470)
Hb, g/l 950 (690–1400) 780 (520–1240) 800 (470–1180) 760 (500–1000)
EPO, u/l 690 (312–8430) 1010 (183–34050) 1010 (355–19570) 1420 (284–6440)
NRBC,/100 WBC 35 (00–3610) 275 (00–6310) 2070 (00–8275) 110 (00–4205)
sTfR, mg/l 246 (99–417) 274 (83–643) 294 (180–565) 317 (224–421)
GDF-15, ng/l 9179 (689–20 234) 8599 (748–53 730) 10,053 (890–46 511) 9114 (1089–30 778)
dw, dry weight; EPO, erythropoietin; GDF-15, growth differentiation factor 15; Hb, haemoglobin; LIC, liver iron concentration; LPI, labile plasma
iron; NRBC, nucleated red blood cell; NTBI, non-transferrin-bound iron; sTfR, soluble transferrin receptor; TfSat, transferrin saturation; WBC,
white blood cells.
TfSat and sTfR levels were progressively increased in patients who received more transfusions and hepcidin levels were notably increased in
patients who received >20 previous transfusions. Note: Data were missing in four patients.
*Negative values can be interpreted as NTBI being absent from the sample.
J. B. Porter et al
294 ª 2016 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
British Journal of Haematology, 2017, 176, 288–299
subgroups. Our findings provide insight into the heterogene-
ity and similarities across NTDT syndromes, as well as the
pathophysiological processes associated with the expanded
erythroid and disordered iron metabolism. Patients enrolled
in the THALASSA study were not currently receiving regular
transfusions or chelation within the past month, but were
sufficiently iron overloaded, as defined by LIC and serum
ferritin levels, to potentially benefit from iron chelation ther-
apy (Taher et al, 2012). Even without a history of transfu-
sions, iron overload occurred across the spectrum of NTDT
subgroups.
Anaemia and hypoxia
Increased markers of anaemia, hypoxia, ineffective erythro-
poiesis and erythroid expansion (sTfR, GDF-15 and NRBC)
were seen across all NTDT subgroups. These markers were
distinctly lower in patients with Hb H syndromes and higher
in those with b TI. Hb E/b thalassaemia patients were, on
average, more anaemic than those with b TI, but EPO levels
were similar to b TI patients (Table II). This is consistent
with the right-shifted oxygen dissociation curve and typically
lower Hb F levels in patients with Hb E/b thalassaemia than
with b TI (Rees et al, 1999). The negative correlation
between Hb levels and EPO across all patient groups sup-
ports the known EPO response to anaemia and hypoxia
(Premawardhena et al, 2005; O’Donnell et al, 2007; Taher
et al, 2011). The weaker relationship between EPO and Hb
in patients with b TI may also be due to increased variability
in the presence of Hb F (Galanello et al, 1994), which was
not measured in this study. The strong negative correlation
of Hb levels with sTfR (Fig 1A) supports the concept that
sTfR levels reflect erythroid mass, which increases with
greater anaemia. Indeed, sTfR levels have been linked with
the incidence of extramedullary erythropoiesis in b TI
patients (Ricchi et al, 2012). It is notable that patients with
the most previous transfusion episodes (>20) had the lowest
Hb values and the highest EPO and sTfR levels, indicative of
a group of patients with the greatest demand on the erythron
when not regularly transfused.
TfSat, NTBI and LPI
Across NTDT subgroups, raised TfSat and NTBI were associ-
ated with increased blood transfusion history, splenectomy,
increased sTfR, increased NRBCs and lower plasma hepcidin.
The strong correlation between TfSat and NTBI, observed for
all NTDT subgroups, is consistent with the relationship previ-
ously identified in haemochromatosis and thalassaemia major
(Loreal et al, 2000; Walter et al, 2008). In this study, NTBI was
predominantly evident in patients when TfSat exceeded
approximately 80%. TfSat is a relatively simple and inexpensive
marker and we would recommend its use when NTBI is not
routinely available. Prior use of transfusions appeared to be a
key factor in the generation of NTBI and TfSat. NTBI was
absent in patients without previous transfusions despite med-
ian LIC values >7 mg Fe/g dw (Table III). This observation
suggests that increased macrophage iron may be a key factor in
the generation of NTBI because patients overloaded from gas-
trointestinal iron absorption alone have predominantly peri-
portal hepatocellular iron, whereas transfusion therapy initially
loads iron to the macrophage compartment (Origa et al,
2007). Rapid egress of iron is the key route to transferrin bind-
ing and, potentially, NTBI generation (Porter et al, 2014). By
contrast, LPI levels showed no obvious relationship to blood
transfusion. LPI was not detected in the majority of patients
(i.e. levels below the ULN of 04 units), whereas other markers
of iron storage and iron turnover were elevated. Raised LPI
levels were mainly confined to those patients with 100% TfSat
[n = 34 (215%); Fig 2D], which explains why, on average, LPI
was generally not raised. These findings suggest that LPI is
unlikely to be a useful marker of small changes in iron overload
in NTDT patients. The binary or hyperbolic relationship of LPI
to TfSat (Fig 2D) also contrasts with the continuum seen
between NTBI and TfSat (Fig 2C), suggesting that NTBI and
LPI identify different iron species in NTDT. As NTDT patients
are typically at lower risk of extra-hepatic iron damage than
TDT patients, where LPI is usually raised, this may be consis-
tent with the notion that LPI is a fraction of NTBI that is more
likely to distribute extra-hepatically (Cabantchik et al, 2005).
Relevance of splenectomy
Higher NTBI values in splenectomised than in non-splenec-
tomised patients have been previously reported for patients
Fig 5. Correlation between serum ferritin and LIC in splenectomised
and non-splenectomised patients. The relationship between LIC and
serum ferritin differed in splenectomised patients, as the serum fer-
ritin increment was greater in relation to LIC. dw, dry weight; LIC,
liver iron concentration.
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with b TI (Taher et al, 2009b). This could represent a more
severe subset of patients who required splenectomy. Further
studies of NTBI (and LPI) in patients pre- and post-splenect-
omy would address this issue. Another explanation, however,
is that splenectomy diverts erythrophagocytosis away from
the spleen, where any NTBI generated would have been
cleared efficiently as a first pass by hepatocytes (Brissot et al,
1985). When erythrophagocytosis is diverted to the marrow,
NTBI clearance by the liver will occur only after systemic cir-
culation and, hence, with higher NTBI levels and greater
extra-hepatic iron uptake.
Erythrocytic expansion and iron overload
The relationship between markers of iron overload and those
of erythron expansion is of mechanistic interest as bone-mar-
row-derived factors, such as erythroferrone (Kautz et al,
2014), are thought to increase iron absorption through sup-
pression of hepcidin. Unfortunately, many patients with b TI
and Hb E/b thalassaemia had received previous transfusion
and chelation therapy, thus obscuring such relationships.
Only in patients with Hb H syndromes, where transfusion
and chelation therapy are rarely used, could relationships
between erythron expansion and iron overload be reliably
explored. Patients with Hb H syndromes received less chela-
tion (only one patient) and had lower splenectomy rates than
other NTDT patient subgroups, even though serum ferritin
levels and LIC were increased to a similar degree. Therefore,
the correlations between markers of iron overload and ery-
throid expansion in patients with Hb H syndromes are of
particular interest and support a relationship between inef-
fective erythropoiesis and increased iron absorption across
NTDT subgroups. These findings should also be considered
in the light of newly discovered markers of ineffective ery-
thropoiesis [e.g. GDF-11 (Dussiot et al, 2014) and erythro-
ferrone (Kautz et al, 2014)], which were reported after the
completion of the THALASSA trial (Taher et al, 2012). Anal-
yses of these biomarkers may provide a more complete inter-
pretation of the relationships between erythrocytic expansion
and iron overload in patients with NTDT.
Fig 6. Median  IQR baseline levels of (A) NTBI, (B) TfSat, (C) GDF-15 and (D) NRBCs in splenectomised and non-splenectomised patients.
Splenectomised patients generally had higher levels of NTBI, TfSat, GDF-15 and NRBCs. GDF-15, growth differentiation factor 15; IQR,
interquartile range; NRBC, nucleated red blood cell; NTBI, non-transferrin-bound iron; TfSat, transferrin saturation.
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Plasma hepcidin
Hepcidin is a key molecule in the regulation of iron
metabolism. Generally, plasma levels are thought to be
increased by iron overload and decreased by erythron expan-
sion. Our findings support a general relationship between
hepcidin and Hb. Hepcidin levels were not elevated above
normal reference ranges across all NTDT subgroups, despite
the presence of iron overload. This is consistent with inhibi-
tory effects from expanded bone marrow (Tanno et al, 2007;
Kautz et al, 2014) outweighing the stimulatory effects of iron
overload. It is of interest that hepcidin levels were least sup-
pressed in patients receiving >20 previous transfusion epi-
sodes (Table III). Another way of examining these competing
effects is with the hepcidin/serum ferritin ratio (Pasricha
et al, 2013). Recently, this ratio (hepcidin *1000/serum fer-
ritin) was found to be higher in controls (ratio = 232) than
in patients with thalassaemia major or SCD (Porter et al,
2014). In the NTDT patients from the THALASSA trial, the
average ratio was approximately 44 across all NTDT sub-
groups (40 in b TI; 60 in Hb E/b thalassaemia; 50 in Hb
H syndromes). This ratio is consistent with moderate gener-
alised hepcidin suppression when corrected for iron overload,
presumably as a consequence of erythroid expansion. In this
cross-sectional analysis, we also showed that plasma hepcidin
in patients with NTDT was more closely related to markers
of iron turnover (TfSat and NTBI) than to iron storage
(serum ferritin and LIC). Therefore, single measurements of
plasma hepcidin are unlikely to be a useful marker of iron
overload in NTDT patients.
LIC and serum ferritin
The importance of the relationship between the two markers
of iron storage, LIC and serum ferritin, lies mainly in the
practical management of iron overload in NTDT patients.
Increased LIC and serum ferritin levels in NTDT patients are
associated with increased morbidities, including vascular,
endocrine and bone diseases (Musallam et al, 2011, 2013,
2014). Serum ferritin underestimates body iron stores in
NTDT patients in comparison with patients with TDT (Pak-
baz et al, 2007; Taher et al, 2008; Lal et al, 2011). However,
clinically relevant serum ferritin thresholds have been identi-
fied (Musallam et al, 2014; Taher et al, 2015), providing a
convenient and inexpensive method of assessing iron overload
and tailoring iron chelation therapy when there is restricted
access to MRI technology. In the present study, the relation-
ship between LIC and serum ferritin was consistent across all
NTDT subgroups. However, the relationship between these
two parameters differed between splenectomised and non-
splenectomised patients as serum ferritin levels were increased
relative to LIC in splenectomised patients. A mechanistic
interpretation requires consideration. The reported lower
serum ferritin levels, relative to LIC, in NTDT versus TDT
patients is probably secondary to early iron deposition in
periportal hepatocytes rather than macrophages (Origa et al,
2007). As serum ferritin at values <3000 lg/l are mainly
derived from macrophages (Worwood et al, 1979), the hepa-
tocellular accumulations are relatively ‘invisible’ to the assay
for serum ferritin. It is likely that splenectomised patients
received more transfusions prior to splenectomy than non-
splenectomised patients, thereby leading to greater iron in the
macrophage system and, hence, higher serum ferritin levels
relative to LIC. Despite these caveats, serum ferritin levels
show the closest relationship to LIC of any of the biomarkers
examined. Indeed, the other biomarkers, while being of
mechanistic interest, do not correlate with LIC closely enough
to justify clinical decisions about chelation therapy to be
made on the basis of their levels.
Conclusions
These analyses add insight into the complex interactions
between anaemia, ineffective erythropoiesis and iron metabo-
lism, as well as previous clinical management across the clini-
cal spectrum of NTDT patients. Importantly, we have
observed increased markers of iron overload across all under-
lying diagnostic syndromes, confirming significant iron bur-
den in NTDT patients who may, therefore, benefit from
optimised iron chelation therapy. A possible relationship of
iron overload to the degree of erythroid expansion was seen in
patients with Hb H syndromes but was obscured in other sub-
groups, most likely due to prior blood transfusions and chela-
tion therapy. These Hb H patients were predominantly
untransfused and we suggest that in such patients, biomarkers
of erythron expansion could, in principle, be predictive of
those patients at most risk of developing iron overload. Future
studies should aim to validate these relationships in larger
patient groups who have not received transfusion or chelation
therapy. Our evidence suggests that NTDT patients are at a
low risk of NTBI- or LPI-mediated extra-hepatic damage
unless blood transfusions exceed 20 episodes and transferrin is
100% saturated. Therefore, the history of transfusional iron
intake, as well as markers or iron overload, should be consid-
ered when assessing patients for iron chelation therapy. The
findings with hepcidin are of mechanistic interest, particularly
the inverse relationship between hepcidin, TfSat, NTBI and
LPI, suggesting that high hepcidin levels may limit TfSat,
NTBI and LPI levels in NTDT patients and, hence, the extra-
hepatic distribution of iron. However, our findings suggest
that hepcidin measurement would not add significantly to the
routine management of NTDT patients. The study patients,
while representing a wide diagnostic spectrum, may not be
fully representative of the full range of NTDT syndromes in
the ‘real world,’ because less iron-overloaded patients were
excluded from this study. Other parameters would be of inter-
est for future studies, such as erythroferrone, a newly
described erythroid regulatory hormone of hepcidin. How-
ever, this study is the most comprehensive examination of fac-
tors associated with iron overload across the NTDT spectrum.
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